Medtronic to Acquire SPR Therapeutics for Chronic Pain Treatment Expansion

Medtronic has announced its intent to acquire SPR Therapeutics for approximately $650 million. This acquisition aims to enhance Medtronic’s neuromodulation portfolio with SPR’s temporary peripheral nerve stimulation technology, enabling earlier interventions for chronic pain sufferers. The SPRINT® PNS System is a 60-day therapy that provides pain relief without requiring a permanent implant. The deal reflects Medtronic’s commitment to expanding patient access to innovative pain relief solutions.